Letter from President & CEO, Hans S. Keirstead

In 2005, California Stem Cell Inc. was founded to address what I perceived to be a critical gap in the path from initial drug discovery to publicly available, clinically proven treatments. Although stem cells were beginning to show great potential in their ability to address human injury and illness, few companies existed with the means and ability to bridge that gap, and were capable of taking on the financial and regulatory challenges present in translating novel academic discoveries into viable cell therapies for patients in need. With that in mind, I set out with a group of highly talented colleagues to create a company capable of doing just that.

With remarkable efficiency, California Stem Cell has created a pipeline of advanced clinical programs testing promising stem cell-based therapies, underpinned by truly outstanding manufacturing and regulatory capabilities.

Now, in 2014, I am happy to announce a change to our organization that we firmly believe will help us better realize our vision. NeoStem, Inc., a leader in the emerging cellular therapy industry, has acquired California Stem Cell in a manner that is mutually beneficial for ourselves, NeoStem, and most importantly, the patients we care so much about. This acquisition will enable us to fund the expansion and advancement of our clinical pipeline of therapies, with additional talent and resources, so we may reach a greater number of patients in a shorter period of time.

The entire team at California Stem Cell is deeply appreciative of the support we have received, proud to announce this major advancement, and committed to the continued growth of our cell therapy pipeline on behalf of patients everywhere.

Sincerely,

Hans S. Keirstead

California Stem Cell (CSC) is focused on the application of high-purity human cells in developing life changing therapies, including a platform cancer technology which has been approved to enter Phase III clinical trials, with Special Protocol Assessment (SPA) and Fast Track designation, in metastatic melanoma.

Since its founding in 2005, CSC has developed proprietary methods for the scalable production of high-purity human stem cells and their derivates. The ability to generate these cell types at high-purity in large quantities has put CSC in the unique position to address critical unmet needs in the development of life-changing therapies. CSC is currently conducting clinical trials investigating its patient specific cancer immunotherapy, a platform technology in development as a treatment for a broad range of cancers.

Cancer Stem Cell

Single platform cancer therapy for the treatment of solid tumor cancers.

Read More

Upcoming Events

Speaking Engagements

Hans Keirstead, Ph.D.

Robert Dillman, M.D.